+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 40Years +
All Genders
ID06677060

Evaluating Baxdrostat Combined With Dapagliflozin to Reduce Heart Failure and Cardiovascular Death Risk Compared to Dapagliflozin Alone

Led by AstraZeneca · Updated on 2026-10-21

11300

Participants Needed

977

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the combination of baxdrostat and dapagliflozin compared with dapagliflozin alone in adults aged 40 years and older who have type 2 diabetes, established cardiovascular disease, a history of hypertension with elevated systolic blood pressure, and at least one additional risk factor for heart failure. This phase III trial aims to assess whether adding baxdrostat can reduce the risk of heart failure events or cardiovascular death. Participants will be randomly assigned to receive either baxdrostat with dapagliflozin or placebo with dapagliflozin. Those not currently on SGLT2 inhibitors or treated for less than 4 weeks will enter a run-in period taking dapagliflozin alone for 4 to 6 weeks before randomization. Doses of baxdrostat may be increased if criteria are met. Study visits occur at 2, 4, 8, 16, and 34 weeks after randomization and then approximately every 4 months until the study ends when enough cardiovascular events have occurred. During the study, participants will have regular assessments including blood pressure and laboratory tests to monitor safety and efficacy. If participants stop the blinded study treatment early, they may continue open-label dapagliflozin. The main outcome is to see if the combination reduces heart failure events or cardiovascular death compared to dapagliflozin alone, with follow-up lasting up to 38 months. Data collection and scheduled visits will continue throughout the study period.

CONDITIONS

Brief Title

Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin

Research Team

A

AstraZeneca Clinical Study Information Center

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here